Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome

Background: The C5 complement inhibitor eculizumab is first-line treatment in atypical hemolytic uremic syndrome (aHUS) going along with a highly increased risk of meningococcal infections. Serogroup B meningococci (MenB) are the most frequently encountered cause for meningococcal infections in Euro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mülling, Nils, Rohn, Hana, Vogel, Ulrich, Claus, Heike, Wilde, Benjamin, Eisenberger, Ute, Kribben, Andreas, Witzke, Oliver, Gäckler, Anja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2020
Materias:
Diagnostics & Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098122/
https://www.ncbi.nlm.nih.gov/pubmed/32159209
http://dx.doi.org/10.1042/BSR20200177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098122/
https://www.ncbi.nlm.nih.gov/pubmed/32159209
http://dx.doi.org/10.1042/BSR20200177

Ejemplares similares